Anca-L Grosu Selected Research

Neoplasms (Cancer)

1/2022	Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.
1/2021	Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
3/2020	Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification.
1/2020	Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
1/2018	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
6/2016	MRI and FDG-PET/CT imaging in gynecological malignancies: the radiation oncology perspective.
7/2014	Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anca-L Grosu Research Topics

Disease

7	Neoplasms (Cancer) 01/2022 - 07/2014
6	Hypoxia (Hypoxemia) 03/2022 - 09/2010
5	Squamous Cell Carcinoma of Head and Neck 03/2022 - 01/2020
4	Prostatic Neoplasms (Prostate Cancer) 11/2020 - 07/2014
4	Glioblastoma (Glioblastoma Multiforme) 01/2018 - 10/2014
3	Meningioma (Meningiomas) 04/2022 - 09/2010
2	Residual Neoplasm 03/2022 - 01/2022
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 07/2015
2	Lymphatic Metastasis 09/2016 - 07/2014
2	Neoplasm Metastasis (Metastasis) 06/2016 - 07/2014
1	Hyperthermia 03/2020
1	Breast Neoplasms (Breast Cancer) 03/2020
1	Glioma (Gliomas) 01/2018
1	Endometrial Neoplasms (Endometrial Cancer) 06/2016
1	Margins of Excision 07/2015
1	Malaria 10/2014

Drug/Important Bio-Agent (IBA)

5	fluoromisonidazoleIBA 03/2022 - 09/2010
3	Biomarkers (Surrogate Marker)IBA 03/2022 - 01/2018
2	MisonidazoleIBA 01/2021 - 01/2020
2	Choline (Choline Chloride)IBA 08/2014 - 07/2014
1	OsteopontinIBA 03/2022
1	Blood Proteins (Serum Proteins)IBA 03/2022
1	Galectin 3 (LGALS3)IBA 03/2022
1	Connective Tissue Growth FactorIBA 03/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	ElementsIBA 01/2022
1	Carbonic Anhydrase IXIBA 01/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	Fluorine-18IBA 01/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018
1	NF-kappa B (NF-kB)IBA 01/2018
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2018
1	Temozolomide (Temodar)FDA LinkGeneric 06/2017
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 10/2015
1	Thalidomide (Thalomid)FDA Link 10/2015
1	TitaniumIBA 07/2015
1	Pharmaceutical PreparationsIBA 10/2014
1	Chloroquine (Aralen)FDA LinkGeneric 10/2014
1	fluoroethylcholineIBA 07/2014
1	Edotreotide (SMT 487)IBA 09/2010
1	Peptides (Polypeptides)IBA 09/2010
1	Biological ProductsIBA 09/2010

Therapy/Procedure

12	Radiotherapy 04/2022 - 07/2015
2	Re-Irradiation 03/2020 - 10/2014
2	Therapeutics 09/2016 - 07/2014
2	Lymph Node Excision (Lymph Node Dissection) 08/2014 - 07/2014
1	Adjuvant Radiotherapy 08/2014